Newsletter · · Ashutosh Agarwal

Healthcare Policy - Drug Pricing, IRA & Managed Care - Week of June 13, 2026: Medicare Advantage Catches a Break; Pharma's Pricing Squeeze Tightens

Healthcare-policy podcast briefing for the week of June 13, 2026. The 2027 Medicare Advantage rate landed better than the January scare, but the IRA pill penalty, Most Favored Nation pricing and a coordinated hospital reimbursement reset tightened the squeeze across UNH, LLY, ELV and the hospital names.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of June 13, 2026: Medicare Advantage Catches a Break; Pharma's Pricing Squeeze Tightens

Two stories dominated the tape this week, and they pull in opposite directions. On the managed-care side, the 2027 Medicare Advantage final rate landed better than the January scare priced in, a rare relief. On the drug-pricing side, the squeeze is going the other way: the IRA's small-molecule penalty is now visibly reshaping where capital flows, and Most Favored Nation pricing is shifting from talking point to planning assumption. Below, what the operators actually said.

TL;DR

  • MA got a reprieve, not a reprieve from scrutiny. CMS finalized a ~2.5% 2027 rate increase and shelved the feared V28 risk-model overhaul on a technical flaw, but an Optum actuary was blunt that it is still "not adequate to keep up with the cost trends," and the V28 rebase is merely deferred to 2028.
  • The IRA "pill penalty" is no longer theoretical. A biotech CEO said plainly he "couldn't get a small molecule company funded because of IRA," and that the industry's pivot from pills to biologics "happened almost instantly."
  • Hospitals face a coordinated reimbursement reset. The new Medicaid state-directed-payment rule, site-neutral expansion, and price-transparency enforcement are landing together, CMS scores the Medicaid piece alone at over $775B over ten years.

What's new

1. The 2027 MA final rate beat the January panic. On Radio Advisory (Jun 9), Alex Balmes, VP of Actuarial Services at Optum (operator), walked through the mechanics: CMS landed at "about a 2.5% increase in overall MA reimbursement," versus the "flat to negative" advance notice that knocked insurer stocks down "as much as 10% to 20% in a single day" in January. The swing factor was risk adjustment, the proposed V28 changes "had a fundamental problem" and weren't adopted, but he warned: "Rolling to 2028, plans should be concerned about this is coming." Why it matters: the relief is real but temporary, and at 2.5% he was direct that "MA is heavily restricted on how you can adjust benefits," meaning member benefit cuts are deferred, not avoided.

2. Lilly leans into direct-to-consumer obesity, with MFN as the backdrop. On On The Pen (Jun 9), host Dave Knapp (pundit) flagged that Lilly is quietly building a pre-approval "expanded access pathway" for retatrutide and that Lilly reps at ADA indicated it will be sold through Lilly Direct. His pricing math is speculation, not company guidance, he noted Most Favored Nation negotiations point to Zepbound cash falling "into the $250 range within 18 months," with retatrutide perhaps "$500 to $800." Why it matters: the cash/DTC channel is becoming the real obesity battleground, and MFN is now the assumed gravity on US list prices.

3. The hospital reimbursement model is being rebuilt, all at once. On Achieving Health (Jun 10), Forvis Mazars reimbursement directors Sean Stack and Chad Mulvaney (advisers) tied three forces into "one coordinated shift": the Medicaid state-directed-payment rule now caps SDPs at a "Medicare-equivalent framework" (CMS scores the Medicaid changes at "over $775 billion in savings over 10 years"), site-neutral expansion threatens "hundreds of billions in payment reductions over time," and price-transparency enforcement "began in earnest in April of 2026." Their verdict: hospitals will have "fewer places to generate margin and fewer places to hide margin," with rural and safety-net systems most exposed. They also flagged a work-requirements interim final rule that will "increase uncompensated care for providers."

4. Commercial affordability is breaking the fully-insured model. On Becker's Payer Issues (Jun 11), Morgan Kendrick, EVP of Commercial Health Benefits at Elevance (operator, 31 years), said "100% of the opportunities that are coming our way to actually bid on coverage are focused on affordability and simplicity," against family premiums up "26% in five years." The shift: even small employers are moving off fully-insured into balanced-funding and multiple-employer welfare arrangements, which he credited with "$400 million in savings in Kentucky and $1.3 billion in Ohio."

5. The IRA pill penalty is now a capital-allocation fact. On Vital Health (Jun 11), biotech CEO Steve Potts (operator) said he used to think regulation was abstract "until I couldn't get a small molecule company funded because of IRA." He noted 2025 was "the second lowest year for small molecule oncology" post-IRA, and that the pivot from small molecules to biologics "already... happened almost instantly," citing Pfizer's wind-down of Array in favor of its ADC franchise. He wants the EPIC Act, which "rationalizes 9[13] and makes it 13[13]," equalizing the small-molecule and biologic negotiation clocks.

The debate: is Medicare Advantage overpaid, or genuinely strained?

The tape this week supported both sides squarely.

Overpaid. Timothy Boulat, who spent nearly 20 years leading MA analytics at Cigna (insider, now in policy), argued on The Podcast by KevinMD (Jun 8) that "taxpayers are actually paying more" for an MA beneficiary than traditional Medicare, with plans optimizing revenue through "coding intensity and favorable selection." He backed continued tightening of risk adjustment and even floated removing the fee-for-service benchmark entirely. His tell on sustainability: MA "grew again in 2026," benefit spending is "at an all-time high," and the "sky is falling" headlines are "overblown."

Strained. Balmes (Optum) countered from the operator seat that the post-COVID "whirlwind" of risk-model changes "has really constrained reimbursement to MA payers" and "compounded financial struggles," and that a 2.5% rate against pharmacy-led cost trend "puts some companies out of business." He noted United "lost a lot of market share this year." Both can be true: plans optimize within the rules and the rules are now tightening into genuine margin pain.

Read-throughs

  • PBMs / Part D: the post-IRA out-of-pocket max steps up from "$2,100 to $2,400" for 2027, which Balmes said is "probably not enough" to curb pharmacy cost growth.
  • Biosimilars / generics: on Health & Veritas (Jun 11), the hosts (academics) flagged a unanimous 9–0 Supreme Court ruling upholding "skinny labeling," preserving the generic on-ramp that keeps drug costs from rising "broadly."
  • Ex-US: the same episode noted Ozempic's patent has come off in Canada, Brazil, China and India (not the US), with generics potentially near "$5," a widening US-vs-rest pricing gap that feeds the MFN argument.
  • Medicaid / exchange insurers (CNC, MOH, ELV): the enhanced premium tax credits "just expired at the end of 2025," which Balmes said means "the ACA line of business is maybe not doing much to bolster the overall portfolio mix."
  • Hospitals (HCA, THC, UHS): the SDP + site-neutral + transparency triple-hit lands hardest on outpatient and Medicaid-heavy systems.
  • GLP-1 exposure / Optum-style services: employers "continue to cut benefits for these meds because of their costs" (Health & Veritas), even as MA pharmacy trend stays hot, a squeeze that runs straight through UNH/Optum.

What changed this week

  • CMS declined to adopt the proposed V28 risk-adjustment changes for 2027, deferred, not dropped.
  • The 2027 MA rate finalized higher than the January advance notice, reversing the worst of the equity drawdown.
  • The Medicaid state-directed-payment rule finalized broader than CBO had penciled in, per the Forvis Mazars reading.